IKT

Inhibikase Therapeutics, Inc. NCM · IKT

$2.17 -0.06 (-2.69%)

Extended · +1.10σ

+ Compare Open in Sniper

Valuation

Market cap $0.3B

P/E (ttm) —

Forward P/E -5.7

Beta (5y) 0.94

Shares out 157.0M

Div yield —

Profitability & returns

ROE -40.2%

Net margin —

FCF margin —

Debt / equity —

Trading information

Last price $2.17

Day range $2.15 – $2.25

52-wk range $1.49 – $2.36

Avg volume 0.8M

RSI (2) 40.9

Trend zone Extended

52-week range · today's price

$1.49$2.36

Company

Sector Healthcare

Industry Biotechnology

Exchange NCM

Next earnings 2026-05-12

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate design…